Posted by Michael Wonder on 05 Jan 2023
Checkpoint Therapeutics submits biologics license application to FDA for cosibelimab as a treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma
4 January 2023 - Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indications.
Checkpoint Therapeutics today announced the submission of a biologics license application to the US FDA for the approval of cosibelimab, its investigational anti-PD-L1 antibody, as a treatment for patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
